Sign up to save your podcasts
Or
Share An Epidural Letdown (4.4.2025)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
An Epidural Letdown (4.4.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
**Correction: a Tweet from 3/18 podcast, had incorrect information. Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to PLACEBO (not deucravacitinib as reported) in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 16 (NOT 15) in 684 moderate-to-severe plaque PsO pts https://buff.ly/dMbTbML
View all episodes
By Dr. Cush
4.7
111111 ratings
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
**Correction: a Tweet from 3/18 podcast, had incorrect information. Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to PLACEBO (not deucravacitinib as reported) in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 16 (NOT 15) in 684 moderate-to-severe plaque PsO pts https://buff.ly/dMbTbML
More shows like Rheumnow Podcast
View all
JAMA Editors' Summary
127 Listeners
NEJM This Week
321 Listeners
JAMA Clinical Reviews
478 Listeners
Mayo Clinic Talks
276 Listeners
The Curbsiders Internal Medicine Podcast
3,317 Listeners
Core IM | Internal Medicine Podcast
1,084 Listeners
The Evidence Based Rheumatology Podcast
110 Listeners
Healio Rheuminations
115 Listeners
Annals On Call Podcast
176 Listeners
The Clinical Problem Solvers
513 Listeners
ACR on Air
63 Listeners
Run the List
245 Listeners
The Curious Clinicians
365 Listeners
Rheumatology For The Royal College
170 Listeners
ACR Journals On Air
18 Listeners